Clinical Trials Logo

Filter by:
NCT ID: NCT02969356 Completed - Spastic Hemiparesis Clinical Trials

Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)

ENGAGE
Start date: December 18, 2016
Phase: Phase 4
Study type: Interventional

The purpose of this clinical study is to assess whether AbobotulinumtoxinA (Dysport®) injections in upper and lower limbs accompanied with a personal exercise plan called "Guided Self-rehabilitation Contract" (GSC) can improve voluntary movements in subjects with hemiparesis.

NCT ID: NCT02968264 Completed - Clinical trials for Congenital Heart Disease

Tetralogy of Fallot for Life

TOF-LIFE
Start date: June 8, 2015
Phase:
Study type: Observational [Patient Registry]

The aim is to conduct a prospective multi-centre international inception cohort study with an enrollment goal of 3,000 TOF patients and 2 year follow-up post-repair. The proposed sample size and methodology will result in statistically powerful results to allow for evidence-based change to current TOF surgical practices.

NCT ID: NCT02967874 Completed - Osteoarthritis Clinical Trials

Autologous Adipose-Derived Stromal Vascular Fraction Cells for Osteoarthritis Treatment

Start date: March 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Adipose-derived stromal vascular fraction cells (SVFs) include regenerative cell populations (hematopoietic cells, pericytes, endothelial cells and progenitors, stromal/stem cells) and thus are potentially important as new therapeutic tools for the repair and regeneration of acute and chronically damaged tissues. The general objective of this study is to evaluate safety and clinical efficacy of a single intra-articular injection of freshly isolated auto-SVFs for the treatment of patients with knee osteoarthritis (OA). This study uses autologous adipose-derived SVFs, as therapeutic agent and intra-articular administration, as a mode of delivery. Expected clinical effects: a treatment reduces pain, increases function and reduces stiffness in the knees of osteoarthritic subjects.

NCT ID: NCT02966353 Completed - Clinical trials for Primary Myelofibrosis

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.

REALISE
Start date: March 31, 2017
Phase: Phase 2
Study type: Interventional

This was a study of treatment with ruxolitinib in patients who presented with transfusion dependent or independent anemia. Starting dose was 10 mg BID. This dose was maintained for the first 12 weeks of the study and up-titrated thereafter unless the subject met criteria for dose hold or dose reduction

NCT ID: NCT02964949 Completed - Atrial Fibrillation Clinical Trials

Comparison of Two Doses of Edoxaban Using Different Tests (Assays) and Clinical Outcomes

Start date: January 24, 2017
Phase: N/A
Study type: Interventional

Atrial fibrillation is when the heart's two upper chambers (called atria) beat chaotically and irregularly, out of coordination with the two lower chambers (called ventricles) of the heart. This can lead to blood clots forming in the heart chamber. Patients with atrial fibrillation will be treated with either 60 mg or 75 mg of edoxaban for up to 12 months, with a 2-4 week follow-up, after which their participation is complete. Blood samples will be collected before the first dose of study drug (Day 0), and on Days 30, 90 and 360 (at pre dose, 1-2 hours post dose and 4-8 hours post-dose).

NCT ID: NCT02964247 Completed - Clinical trials for Diabetes Mellitus, Type 2

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

Start date: March 3, 2017
Phase: Phase 3
Study type: Interventional

The trial is conducted in Asia, Europe, North America and South America. The aim of the study is to compare the effect of liraglutide 1.8 mg/day versus placebo as add-on to an SGLT2 inhibitor with or without metformin on glycaemic control in subjects with type 2 diabetes mellitus.

NCT ID: NCT02963506 Completed - Clinical trials for Ankylosing Spondylitis

A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis

BE AGILE
Start date: October 2016
Phase: Phase 2
Study type: Interventional

This is a study to evaluate the efficacy and safety of different doses of bimekizumab in subjects with active Ankylosing Spondylitis (AS).

NCT ID: NCT02962895 Completed - Clinical trials for Primary Sjogren Syndrome

Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

Start date: June 27, 2017
Phase: Phase 2
Study type: Interventional

This study will determine the dose-response relationship of VAY736 for key efficacy and safety parameters

NCT ID: NCT02958865 Completed - Ulcerative Colitis Clinical Trials

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Start date: February 3, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.

NCT ID: NCT02957682 Completed - Clinical trials for Hypercholesterolemia

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Start date: November 2, 2016
Phase: Phase 4
Study type: Interventional

The main purpose of this study is to evaluate the effect on mental state (known as "neurocognitive function") with use of Praluent.